132
Participants
Start Date
May 1, 2018
Primary Completion Date
December 31, 2020
Study Completion Date
April 1, 2021
CP101
Study drug will be administered at Treatment (Day 1) as an oral dose after cessation of standard-of-care CDI antibiotic treatment of the current episode of recurrent CDI.
New York, New York
New York, New York
New York, New York
Bronx, The Bronx
Washington DC, Washington D.C.
Annandale, Annandale
Charlottesville, Charlottesville
Winston-Salem, Winston-Salem
Winston-Salem, Winston-Salem
Chapel Hill, Chapel Hill
Pinehurst, Pinehurst
Kinston, Kinston
Atlanta, Atlanta
Jacksonville, Jacksonville
Tampa, Tampa
Pinellas Park, Pinellas Park
Naples, Naples
Nashville, Nashville
Poland, Poland
Cincinnati, Cincinnati
Indianapolis, Indianapolis
Royal Oak, Royal Oak
Detroit, Detroit
West Des Moines, West Des Moines
Grafton, Grafton
St. Paul, Saint Paul
Rochester, Rochester
Butte, Butte
Maywood, Maywood
Evanston, Evanston
Burr Ridge, Burr Ridge
Chicago, Chicago
Shawnee, Shawnee Mission
New Orleans, New Orleans
San Antonio, San Antonio
Aurora, Aurora
Idaho Falls, Idaho Falls
Salt Lake City, Salt Lake City
Ogden, Ogden
Scottsdale, Scottsdale
Los Angeles, Los Angeles
San Diego, San Diego
Murrieta, Murrieta
San Francisco, San Francisco
Oakland, Oakland
Portland, Portland
Seattle, Seattle
Bridgeport, Bridgeport
Hamden, Hamden
Boston, Boston
Morristown, Morristown
Somers Point, Somers Point
Providence, Providence
Calgary, Calgary
Halifax, Halifax
London, London
Toronto, Toronto
Lead Sponsor
Collaborators (1)
Medpace, Inc.
INDUSTRY
Finch Research and Development LLC.
INDUSTRY